CohBar’s mission is to treat age-related diseases and extend healthy life spans through the discovery, optimization and development of novel mitochondrial-derived peptides into clinically relevant and commercially successful mitochrondria based therapeutics.
We believe CohBar is a first mover in exploring the mitochondrial genome to identify MDPs with the potential to be developed into transformative medicines. Our strategy is to secure a leading scientific and intellectual property position in mitochondrial peptides, as we continue to identify new peptides with potential for metabolic regulation and protection, and develop drug candidates that address the metabolic dysfunction underlying age-related diseases.
Our proprietary platform technology involves exploring the mitochondrial genome for new peptides that exhibit biological activity, and optimizing their structures using cell based and preclinical models to develop proprietary MBTs with the potential to treat a range of age-related diseases. To date, CohBar’s scientific team and our founders have discovered more than 50 biologically active mitochondrial-derived peptides.
Mitochondria, the only parts of the cell other than the nucleus that have their own genome, produce energy and regulate cell death in response to signals received from the cell. Until recently, scientists believed the mitochondrial genome contained a limited number of genes and, as a result, it had been relatively unexplored as a focus of drug discovery efforts. Research by CohBar founders and their academic collaborators revealed that the mitochondrial genome contains significantly more potential new genes that encode various peptides. In preclinical models of age-related diseases, a number of these mitochondrial-derived peptides (MDPs) have shown potential disease-modifying effects including metabolic regulation, neuro-protective, cyto-protective and anti-inflammatory activity.
The original groundbreaking research in the areas of mitochondrial genomics and biology, age-related diseases, longevity, metabolism and MDP’s underlying our licensed intellectual property portfolio was conducted by our Founders, Dr. Pinchas Cohen, Dean of the Davis School of Gerontology at the University of Southern California, Dr. Nir Barzilai, Professor of Genetics and Director of the Institute for Aging Research at the Albert Einstein College of Medicine, and their academic collaborators. Our Founders’ research has been supported by grants totaling over $30 million awarded to their respective academic institutions since 2001 by the National Institutes of Health, private foundations, and other grant funding organizations.
The multi-disciplinary expertise of our scientific leaders, and their investigations into and knowledge of age-related diseases, has enabled and focused our research efforts on the mitochondrial genome and its potential to yield biologically active peptides for therapeutic advancement.